BR112012032185A2 - anticorpos úteis na imunização passiva de influenza. - Google Patents

anticorpos úteis na imunização passiva de influenza.

Info

Publication number
BR112012032185A2
BR112012032185A2 BR112012032185A BR112012032185A BR112012032185A2 BR 112012032185 A2 BR112012032185 A2 BR 112012032185A2 BR 112012032185 A BR112012032185 A BR 112012032185A BR 112012032185 A BR112012032185 A BR 112012032185A BR 112012032185 A2 BR112012032185 A2 BR 112012032185A2
Authority
BR
Brazil
Prior art keywords
influenza
passive immunization
antibodies useful
antibodies
useful
Prior art date
Application number
BR112012032185A
Other languages
English (en)
Inventor
Krista Maureen Mccutcheon
Lawrence M Kauvar
Minha Park
Stote Ellsworth
William Usinger
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of BR112012032185A2 publication Critical patent/BR112012032185A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos úteis na imunização passiva de influenza. os articorpos monoclonais e seus fragmentos que são reação cruzada com múltiplos subtipos de vírus da gripe, incluindo tanto o grupo 1 e grupo 2 representantes são divulgados. estes anticorpos são úteis no controlo de epidemias de gripe e pandemias, bem como o fornecimento de proteção profilática ou terapêutica contra a gripe sazonal.
BR112012032185A 2010-06-17 2011-06-17 anticorpos úteis na imunização passiva de influenza. BR112012032185A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US201161445455P 2011-02-22 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (1)

Publication Number Publication Date
BR112012032185A2 true BR112012032185A2 (pt) 2016-10-11

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032185A BR112012032185A2 (pt) 2010-06-17 2011-06-17 anticorpos úteis na imunização passiva de influenza.

Country Status (12)

Country Link
US (1) US10676520B2 (pt)
EP (1) EP2582721B1 (pt)
JP (1) JP6050747B2 (pt)
KR (1) KR101849738B1 (pt)
CN (2) CN106397584A (pt)
AU (2) AU2011268072C1 (pt)
BR (1) BR112012032185A2 (pt)
CA (1) CA2839421C (pt)
DK (1) DK2582721T3 (pt)
ES (1) ES2687706T3 (pt)
RU (1) RU2635999C2 (pt)
WO (1) WO2011160083A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
MX2015005860A (es) 2012-11-13 2015-08-10 Genentech Inc Anticuerpos de antihemaglutinina y metodo de uso.
AU2014236508A1 (en) 2013-03-14 2015-09-17 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
EP3102598A2 (en) 2014-02-04 2016-12-14 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
JP2019529345A (ja) * 2016-07-14 2019-10-17 バイオアークティック アクティエボラーグ 脳送達タンパク質
CN111989115A (zh) * 2017-12-29 2020-11-24 财团法人生物技术开发中心 针对流感的通用疫苗
WO2019147867A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
JP2022521819A (ja) 2019-03-25 2022-04-12 ビステラ， インコーポレイテッド インフルエンザを処置および予防するための組成物および方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
EP1603590A4 (en) 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
KR101206206B1 (ko) 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
RU2366662C2 (ru) * 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
MY170607A (en) * 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2222701B1 (en) * 2007-12-06 2017-11-01 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
JP2011528902A (ja) 2008-07-25 2011-12-01 インスティテュート・フォー・リサーチ・イン・バイオメディシン 抗ａ型インフルエンザウイルス中和抗体およびその使用
CL2009001735A1 (es) * 2008-08-19 2010-02-19 Regeneron Pharma Anticuerpo humano o fragmento de union a antigeno del mismo que une e inhibe actividad de ligando del activador del receptor de nf-kb (rankl); adn codificante; vector de expresion; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; uso para atenuar o inhibir enfermedad o condicion mediada por rankl
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EA029198B1 (ru) 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
JP2013540701A (ja) * 2010-08-12 2013-11-07 セラクローン サイエンシーズ， インコーポレイテッド 抗赤血球凝集素抗体組成物およびその使用方法
US20130289246A1 (en) * 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Also Published As

Publication number Publication date
EP2582721A1 (en) 2013-04-24
JP2013531993A (ja) 2013-08-15
KR20130137584A (ko) 2013-12-17
WO2011160083A1 (en) 2011-12-22
DK2582721T3 (en) 2018-10-01
EP2582721B1 (en) 2018-08-22
US20120020971A1 (en) 2012-01-26
KR101849738B1 (ko) 2018-04-17
US10676520B2 (en) 2020-06-09
AU2011268072A1 (en) 2013-01-31
EP2582721A4 (en) 2013-11-20
AU2017203924A1 (en) 2017-07-06
JP6050747B2 (ja) 2016-12-21
RU2635999C2 (ru) 2017-11-17
CN103209994A (zh) 2013-07-17
CA2839421C (en) 2019-12-03
CN103209994B (zh) 2016-10-12
CA2839421A1 (en) 2011-12-22
CN106397584A (zh) 2017-02-15
AU2011268072B2 (en) 2017-03-09
AU2011268072C1 (en) 2017-10-19
AU2011268072A2 (en) 2013-02-28
RU2013102073A (ru) 2014-07-27
AU2017203924B2 (en) 2019-08-08
ES2687706T3 (es) 2018-10-26

Similar Documents

Publication Publication Date Title
BR112012032185A2 (pt) anticorpos úteis na imunização passiva de influenza.
BR112014013640A2 (pt) anticorpos úteis na imunização passiva contra influenza
NI201800052A (es) Anticuerpos que neutraliza el virus respiratorio sincitial humano
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
ECSP11010823A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BRPI0909123A2 (pt) anticorpos monoclonais capazes de reagir com uma pluralidade de subtipos de vírus de influenza a
WO2013020074A3 (en) A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
WO2013081463A3 (en) Influenza a virus specific antibodies
BR112014003315A2 (pt) composições e métodos relacionados a anticorpos para a proteína a estafilocócica
BR112015007616A2 (pt) inibidores de mek no tratamento de doenças por vírus
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
MX370191B (es) Composiciones y su uso en el tratamiento de la inmunodeficiencia.
BRPI0814899A2 (pt) Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112013000394A2 (pt) composições e métodos para o tratamento de influenza
BR112016006210A2 (pt) terapia e vacina contra gripe
BR112016005601A8 (pt) composto, composição farmacêutica, e usos de um composto
BR112014003278A2 (pt) vacinas para influenza h5
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3
WO2009054708A3 (en) Antibody therapy for highly pathogenic avian influenza virus
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
WO2013173256A3 (en) New and improved influenza vaccines
MX2015012399A (es) Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: TRELLIS BIOSCIENCE, INC (US)

B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2675 DE 12-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.